"10.1371_journal.pone.0146679","plos one","2016-01-11T00:00:00Z","Katrin Frauenknecht; Kai Diederich; Petra Leukel; Henrike Bauer; Wolf-Rüdiger Schäbitz; Clemens J Sommer; Jens Minnerup","Institute of Neuropathology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany; Department of Neurology, University of Münster, Münster, Germany; Neurology, Bethel, EVKB, Bielefeld, Germany","Conceived and designed the experiments: WRS CJS JM. Performed the experiments: KF KD PL HB. Analyzed the data: KF PL HB. Contributed reagents/materials/analysis tools: WRS CJS. Wrote the paper: KF KD CJS JM.","CS and WRS are inventors on the patent application Hematopoietic factors for treatment of neurological condition including stroke and other diseases. Recently a part of the application (ALS) was granted. CS and WRS transferred their rights to Sygnis and received a minor financial compensation upfront. In case of efficacy CS and WRS participate in form of royalties. Furthermore, CS and WRS neither hold nor receive stocks of Sygnis nor have direct interest in the company. WRS received compensation in form of honoraria in his function as PI of the AXIS I study as indicated in this particular publication (Schabitz et al., Stroke, 2010;41:2545-51). Treatment of neurological disorders with haematopoietic growth factors”; 10007362.6-2107; US 10/331,755; Continuation US 10/659,295; PCT/IB03/006446; US 10/880,101; PCT/IB2004/004329). This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2016","01","Katrin Frauenknecht","KF",7,TRUE,3,4,3,4,TRUE,TRUE,FALSE,0,NA,FALSE
